Rick Doblin, legendary founder of MAPS, discusses his views on the recent unexpected decision by the FDA to delay the approval of MDMA-Assisted Therapy for broad clinical use. In this interview, Rick clarifies each point raised against MDMA therapy in the recent controversy, then counters and dispels most of the criticism that was raised against the studies.